New Treatments in IBD

June 29, 2023
Foundation logo
Jointly provided by
Post Graduate Institute of Medicine
Virtual Event
Register here
Date & Time
June 29, 2023
7:00 pm - 8:00 pm ET

Join us for the next Professional Webinar Series presentation titled “New Treatments in IBD”. The talk will include new medications, positioning, real world evidence, and the Foundation's EMR IBD Education Tool. The 45 minute presentation will be followed by a 15 minute question and answer session with the presenters.

Program Faculty:

Miguel Regueiro, MD, Cleveland Clinic

Katie Falloon, MD, Cleveland Clinic

Shuba Bhat, PharmD, Cleveland Clinic

1.0 AMA, ANCC, ACPE Credits

Time Program Details
7:00 p.m. - 7:45 p.m. ET New Treatments in IBD Presentation
7:45 p.m. - 8:00 p.m. ET Q & A with Faculty




Shubha Bhat, PharmD, BCACP

Cleveland Clinic



Miguel Regueiro, MD

Cleveland Clinic



Katie Falloon, MD

Cleveland Clinic


Event Day

Zoom login will be emailed to attendees prior to the program. 

CE Information

Target Audience

This activity is intended for physicians, APPs, Nurses, pharmacists and multi-disciplinary team members who are engaged in the care of patients with inflammatory bowel disease (IBD) in primary care, managed care organizations, ambulatory care, and hospital settings.


Educational Objectives
After completing this activity, the participant should be better able to:

• Discuss treatments for patients with IBD, taking into consideration disease history, disease severity, and patient preference
• Demonstrate shared decision-making and co-production models that facilitate open provider/patient dialogue
• Optimize communication methods and empower patients
• Recognize the impact of IBD on patients and
• Apply evidence-based IBD pathways in patient education and shared decision-making
• Implement co-productive patient-provider strategies including key learnings from clinical trial results and emerging research in IBD into clinical practice to improve overall patient outcomes
• Identify areas of miscommunication and engage patients on management expectations for Crohn’s and UC


Joint Accreditation Statement 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Crohn’s & Colitis Foundation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation:

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.


Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008162-9999-23-162-L01-P
Type of Activity: Knowledge


Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.

Miguel Regueiro, M.D. receives the following financial support:

Unrestricted Educational Grants from Abbvie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, Gilead, BMS, Lilly

Advisory Boards and Consultant for Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A., BMS

CME Companies: CME Outfitters, Imedex, GI Health Foundation (GiHF), Cornerstones, Remedy, MJH life sciences, Medscape, MDEducation, WebMD, HMPGlobal

Royalties and Editorships: Wolters Kluwer Health as Author/Editor of UpToDate, Crohn’s and Colitis Foundation as Editor-in-Chief, CC360

Katie Fallon, MD receives the following financial support:

Grants and Research Support: Crohn’s and Colitis Foundation Clinical Research Alliance Award

Advisory Boards: GI Fellow Advisory Board for Janssen

Shubha Bhat, PharmD receives the following financial support:

Speakers Bureau/Honoraria for non-CME: Eli Lilly, Prometheus Lab

Consultant/Advisory Board: AbbVie, Bristol-Myers Squibb, Prometheus Lab, Boehringer Ingelheim, Pfizer


 Fee Information

There is no fee for this educational activity.


For more information, please contact Dan Schneiderjohn, Senior Manager, Professional Education  at [email protected]